Katsumi, Yoshiki <br/><br/>
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2008 
 - 1192-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-1661  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antibody-Dependent Cell Cytotoxicity<br/>Antineoplastic Agents--pharmacology<br/>Blotting, Western<br/>Cell Line, Tumor<br/>Female<br/>Flow Cytometry<br/>Fluorescent Antibody Technique<br/>Humans<br/>Immunohistochemistry<br/>Infant<br/>Infant, Newborn<br/>Interleukin-2--pharmacology<br/>Leukocytes, Mononuclear--immunology<br/>Male<br/>Receptor, ErbB-2--biosynthesis<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Rhabdoid Tumor--immunology<br/>Trastuzumab